LOS ANGELES, Aug 19 (Reuters) - Seattle Genetics (SGEN.O), a developer of antibody-based drugs, could have important data as soon as this month from a trial of its experimental leukemia treatment, followed within weeks by results from two trials of another drug for lymphoma.
